atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
July 07 2021 - 7:47PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company developing psychedelic and
non-psychedelic compounds for various mental health indications,
today announced that it will present and participate in one-on-one
investor meetings at the Cowen Psychedelics & Novel Mechanisms
in Neuropsychiatry Summit on July 13, 2021.
Presentation details can be found below.
Date: |
Tuesday, July 13, 2021 |
Time: |
10:50 AM ET |
Webcast link: |
https://wsw.com/webcast/cowen86/atai/1936406 |
A replay of the presentation will be available in the “Events”
section of the atai Life Sciences website at ir.atai.life.
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape. atai is dedicated to
acquiring, incubating and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders. atai's business model combines funding,
technology, scientific and regulatory expertise with a focus on
psychedelic therapy and other drugs with differentiated safety
profiles and therapeutic potential. By pooling resources and best
practices, atai aims to responsibly accelerate the development of
new medicines across its companies, seeking to effectively treat
and ultimately heal mental health disorders. atai's mission is to
bridge the gap between what the mental healthcare system currently
provides and what patients need. atai is headquartered in Berlin,
with offices in New York. For more information, please visit
www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements, including without limitation
statements regarding atai’s participation in upcoming conferences
and presentations and similar statements of a future or
forward-looking nature. Forward-looking statements are neither
promises nor guarantees, but involve known and unknown risks and
uncertainties that could cause actual results to differ materially
from those projected, including, without limitation, the important
factors discussed under the caption “Risk Factors” in atai's
prospectus pursuant to Rule 424(b) filed with the U.S. Securities
and Exchange Commission (“SEC”) on June 21, 2021, as such factors
may be updated from time to time in atai's other filings with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof and accordingly undue reliance
should not be placed on such statements. atai disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, whether as a result of
new information, future events or otherwise, other than to the
extent required by applicable law.
Investor Contact:Greg Weaveratai – Chief
Financial OfficerEmail: greg.weaver@atai.life
Media Contact:Anne DonohoeKCSA Strategic
CommunicationsPhone: +1 (212) 896-1265Email:
atai@KCSA.com
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Apr 2023 to Apr 2024